AstraZeneca, european medicines agency and lung cancer
AstraZeneca, Daiichi Sankyo Withdraw Authorization Application for Lung Cancer Treatment in EU
AstraZeneca said it and Daiichi Sankyo decided to voluntarily withdraw the marketing authorization application in the European Union for advanced lung-cancer treatment Dato-DXd. This decision followed a feedback from the European Medicines Agency, the pharma company said Tuesday.
European stocks edged higher in cautious trade on Tuesday ahead of Christmas break. The German DAX is not trading today while the ...
Anavex (AVXL) stock rallied 30% Monday after the company announced EU regulators had accepted the market application for its ...
Biocon Ltd, in collaboration with Zentiva, has obtained EU approval for the complex formulation Liraglutide, a generic ...
Catch up on all the latest pharma industry news from the past month, from breakthroughs in gene therapy to promising drug ...
The European Union’s drug regulator said it would review two studies that link Novo Nordisk’s blockbuster diabetes drug ...
Following an appeal by the Danish Medicines Agency, the European Union’s drug regulator will review two new studies that have ...
The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...
AstraZeneca ( (GB:AZN) ) has shared an update. AstraZeneca and Daiichi Sankyo have withdrawn their EU marketing application for datopotamab deruxtecan for advanced nonsquamous non-small cell lung ...
Bristol Myers Squibb BMY announced that the European Commission has approved the combination of its blockbuster ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback